TW200600505A - Compounds and compositions as ppar modulators - Google Patents

Compounds and compositions as ppar modulators

Info

Publication number: TW200600505A
Authority: TW; Taiwan
Prior art keywords: compounds; compositions; ppar modulators; activity; ppar
Prior art date: 2004-05-24

Application number

TW094116634A

Other languages

English (en)

Inventor

Christopher Cow

Robert Epple

Ross Russo

Xing Wang

yong-ping Xie

Original Assignee

Irm Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-05-24

Filing date

2005-05-23

Publication date

2006-01-01

2005-05-23 Application filed by Irm Llc filed Critical Irm Llc

2006-01-01 Publication of TW200600505A publication Critical patent/TW200600505A/zh

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/10—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/10—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D263/14—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with radicals substituted by oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Cardiology (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Neurology (AREA)
Obesity (AREA)
Hematology (AREA)
Rheumatology (AREA)
Neurosurgery (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Biomedical Technology (AREA)
Hospice & Palliative Care (AREA)
Child & Adolescent Psychology (AREA)
Emergency Medicine (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Ophthalmology & Optometry (AREA)
Vascular Medicine (AREA)
Endocrinology (AREA)
Psychiatry (AREA)
Pulmonology (AREA)
Immunology (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

TW094116634A 2004-05-24 2005-05-23 Compounds and compositions as ppar modulators TW200600505A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US57413704P	2004-05-24	2004-05-24
US64967105P	2005-02-02	2005-02-02

Publications (1)

Publication Number	Publication Date
TW200600505A true TW200600505A (en)	2006-01-01

Family

ID=35450825

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW094116634A TW200600505A (en)	2004-05-24	2005-05-23	Compounds and compositions as ppar modulators

Country Status (17)

Country	Link
US (1)	US20070244130A1 (zh)
EP (1)	EP1749003A4 (zh)
JP (1)	JP2008500354A (zh)
KR (1)	KR20070043705A (zh)
AR (1)	AR049186A1 (zh)
AU (2)	AU2005247930B2 (zh)
BR (1)	BRPI0511527A (zh)
CA (1)	CA2563819A1 (zh)
EC (1)	ECSP067019A (zh)
IL (1)	IL179375A0 (zh)
MA (1)	MA28900B1 (zh)
MX (1)	MXPA06013589A (zh)
NO (1)	NO20065983L (zh)
PE (1)	PE20060362A1 (zh)
RU (1)	RU2412175C2 (zh)
TW (1)	TW200600505A (zh)
WO (1)	WO2005116016A1 (zh)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2625646A1 (en) *	2005-10-25	2007-05-03	Merck & Co., Inc.	Combination of a dipeptidyl peptidase-4 inhibitor and an anti-hypertensive agent for the treatment of diabetes and hypertension
KR20080056288A (ko) *	2005-11-07	2008-06-20	아이알엠 엘엘씨	Ｐｐａｒ 조절제로서의 화합물 및 조성물
AU2008218951B2 (en) *	2007-02-22	2011-11-17	Irm Llc	Compounds and methods for modulating g protein-coupled receptors
EP1972335A1 (en) *	2007-03-23	2008-09-24	Krka	Solid dosage forms comprising aliskiren and pharmaceutically acceptable salts thereof
KR100860561B1 (ko) *	2007-05-02	2008-09-26	경희대학교 산학협력단	컴파운드 ｋ 및 메트포민을 유효성분으로 포함하는당뇨병의 예방 및 치료용 약학적 조성물
US20100113603A1 (en) *	2008-10-16	2010-05-06	Aronne Louis J	Combination therapies for the treatment of obesity
US20100113604A1 (en) *	2008-10-16	2010-05-06	Aronne Louis J	Combination therapies for the treatment of obesity
US20100113581A1 (en) *	2008-10-16	2010-05-06	Aronne Louis J	Combination therapies for the treatment of obesity
US20100113583A1 (en) *	2008-10-16	2010-05-06	Aronne Louis J	Combination therapies for the treatment of obesity
WO2010151503A2 (en) *	2009-06-25	2010-12-29	Metabolous Pharmaceuticals, Inc.	Combination therapies for the treatment of obesity
WO2010151565A2 (en) *	2009-06-26	2010-12-29	Metabolous Pharmaceuticals, Inc.	Combination therapies for the treatment of obesity
WO2011008490A2 (en) *	2009-06-29	2011-01-20	Metabolous Pharmaceuticals, Inc.	Combination therapies for the treatment of obesity
US20110015663A1 (en) *	2009-07-17	2011-01-20	Aronne Louis J	Combination Therapies for the Treatment of Obesity
KR20120051668A (ko) *	2009-08-05	2012-05-22	다이이찌 산쿄 가부시키가이샤	술폰 유도체
MY156174A (en)	2009-08-05	2016-01-15	Daiichi Sankyo Co Ltd	4-(1,2,4-dioxazol-3-yl)benzamides for the treatment of diabetes and obesity
WO2011041632A2 (en) *	2009-10-01	2011-04-07	Metabolous Pharmaceuticals, Inc.	Combination therapies for the treatment of obesity
US8652527B1 (en)	2013-03-13	2014-02-18	Upsher-Smith Laboratories, Inc	Extended-release topiramate capsules
US9101545B2 (en)	2013-03-15	2015-08-11	Upsher-Smith Laboratories, Inc.	Extended-release topiramate capsules
CN103724289B (zh) *	2013-12-23	2015-08-19	同济大学	(e)-2,4,5-三取代-(1-丙烯基)噁唑环类化合物及合成方法和应用
CN104402839B (zh) *	2014-10-20	2016-11-02	同济大学	一种(e)-2,4,5-三取代-(1-丙烯基)噁唑环类化合物及其制备方法
CN108760940A (zh) *	2018-08-03	2018-11-06	安徽省金楠医疗科技有限公司	一种硫酸氢氯吡格雷检测方法
CN112521384B (zh) *	2021-01-13	2021-11-02	湖北大学	溶剂热一锅法合成苯并噻嗪并环戊二烯衍生物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4325959A (en) *	1979-08-09	1982-04-20	The Dow Chemical Company	Hypoglycemic 4-(((1,3,4, thiadiazolyl)thio)methyl)benzoic acids, ester and amides
JPH0662590B2 (ja) *	1986-09-19	1994-08-17	久光製薬株式会社	新規なベンズオキサゾ−ル誘導体
IT1229491B (it) *	1988-12-28	1991-09-03	Roussel Maestretti S P A Ora R	Derivati della 1,2,5,6-tetraidropiridina, loro procedimento di preparazione e loro impiego come sostanze medicinali
US5262540A (en) *	1989-12-20	1993-11-16	Bristol-Myers Squibb Company	[2(4,5-diaryl-2 oxazoyl substituted phenoxy alkanoic acid and esters
NZ236474A (en) *	1989-12-20	1993-07-27	Bristol Myers Squibb Co	4,5-diphenyl-2-oxazole octanoic, nonanoic and decanoic acid and ester derivatives, preparation and pharmaceutical compositions thereof
EP0440183A1 (en) *	1990-02-01	1991-08-07	Takeda Chemical Industries, Ltd.	Oxazole compounds, their production and use
IT1248528B (it) *	1991-06-21	1995-01-19	Pierrel Spa	Derivati di eteri e tioeteri (etero) aromatici aventi attivita` antiiperlipidemica, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono.
JPH06206805A (ja) *	1992-02-17	1994-07-26	Hisamitsu Pharmaceut Co Inc	チロシナーゼ阻害剤及びそれを用いた皮膚外用剤
RU2032677C1 (ru) *	1992-05-05	1995-04-10	Бристоль-Мейерз Сквибб Компани	Производные оксазола
US5380738A (en) *	1993-05-21	1995-01-10	Monsanto Company	2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
JPH11147881A (ja) *	1997-08-21	1999-06-02	Sankyo Co Ltd	ジヒドロベンゾキノン骨格を有する除草性アゾール誘導体
JP2002348281A (ja) *	2001-03-23	2002-12-04	Takeda Chem Ind Ltd	５員複素環アルカン酸誘導体

2005
- 2005-05-20 PE PE2005000563A patent/PE20060362A1/es not_active Application Discontinuation
- 2005-05-23 AR ARP050102114A patent/AR049186A1/es unknown
- 2005-05-23 TW TW094116634A patent/TW200600505A/zh unknown
- 2005-05-24 AU AU2005247930A patent/AU2005247930B2/en not_active Ceased
- 2005-05-24 WO PCT/US2005/018166 patent/WO2005116016A1/en not_active Ceased
- 2005-05-24 US US11/597,260 patent/US20070244130A1/en not_active Abandoned
- 2005-05-24 BR BRPI0511527-2A patent/BRPI0511527A/pt not_active IP Right Cessation
- 2005-05-24 KR KR1020067024605A patent/KR20070043705A/ko not_active Ceased
- 2005-05-24 JP JP2007515254A patent/JP2008500354A/ja active Pending
- 2005-05-24 CA CA002563819A patent/CA2563819A1/en not_active Abandoned
- 2005-05-24 EP EP05775612A patent/EP1749003A4/en not_active Withdrawn
- 2005-05-24 MX MXPA06013589A patent/MXPA06013589A/es not_active Application Discontinuation
- 2005-05-24 RU RU2006145893/04A patent/RU2412175C2/ru not_active IP Right Cessation
2006
- 2006-11-16 IL IL179375A patent/IL179375A0/en unknown
- 2006-11-21 EC EC2006007019A patent/ECSP067019A/es unknown
- 2006-12-12 MA MA29525A patent/MA28900B1/fr unknown
- 2006-12-22 NO NO20065983A patent/NO20065983L/no not_active Application Discontinuation
2009
- 2009-07-01 AU AU2009202673A patent/AU2009202673A1/en not_active Abandoned

Also Published As

Publication number	Publication date
AU2009202673A1 (en)	2009-07-23
MXPA06013589A (es)	2007-03-15
IL179375A0 (en)	2007-03-08
AU2005247930B2 (en)	2009-04-02
AR049186A1 (es)	2006-07-05
AU2005247930A1 (en)	2005-12-08
KR20070043705A (ko)	2007-04-25
WO2005116016A1 (en)	2005-12-08
US20070244130A1 (en)	2007-10-18
ECSP067019A (es)	2006-12-29
RU2412175C2 (ru)	2011-02-20
EP1749003A4 (en)	2010-05-05
JP2008500354A (ja)	2008-01-10
PE20060362A1 (es)	2006-05-15
MA28900B1 (fr)	2007-10-01
RU2006145893A (ru)	2008-06-27
EP1749003A1 (en)	2007-02-07
BRPI0511527A (pt)	2008-01-02
CA2563819A1 (en)	2005-12-08
NO20065983L (no)	2007-02-05

Publication	Publication Date	Title
TW200612926A (en)	2006-05-01	Compounds and compositions as ppar modulators
MX2007009356A (es)	2007-12-07	Compuestos y composiciones como moduladores de ppar.
TW200602330A (en)	2006-01-16	Compounds and compositions as PPAR modulators
TW200600505A (en)	2006-01-01	Compounds and compositions as ppar modulators
ATE478072T1 (de)	2010-09-15	Spiroimidazol-derivate als ppar-modulatoren
ATE445624T1 (de)	2009-10-15	Verbindungen und zusammensetzungen als ppar- modulatoren
WO2007089557A3 (en)	2007-11-08	Polycyclic 1, 2, 3, 4 -tetrahydro- isoquinoline derivatives and compositions comprising them as ppar modulators
MX2009006339A (es)	2009-08-21	Compuestos y composiciones como inhibidores de actividad de receptor 1 de cannabinoide.
TNSN07161A1 (en)	2008-11-21	Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
MX2008012400A (es)	2008-10-10	Azolopirimidinas como inhibidores de actividad de cannabinoide 1.
MX2010003117A (es)	2010-04-01	Compuestos y composiciones como moduladores de la actividad de gpr119.
PL2134704T3 (pl)	2011-03-31	Związki i kompozycje pełniące rolę modulatorów aktywności GPR119
TW200738724A (en)	2007-10-16	Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
MX2007005205A (es)	2007-05-11	Compuestos biciclicos sulfonilo-sustituidos como moduladores de receptores activados por el proliferador de la peroxisoma.
TW200608979A (en)	2006-03-16	Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
IL195256A0 (en)	2009-08-03	Compositions of r(+)and s(-)pramipexole and methods of using the same
GEP20094844B (en)	2009-11-25	3-aminocyclopentane carboxamides as modulators of chemokine receptors
GEP20094843B (en)	2009-11-25	3-aminocyclopentane carboxamides as modulators of chemokine receptors
BRPI0510024A (pt)	2007-09-25	compostos e composições como modulares de ppar
WO2007056366A3 (en)	2007-07-05	Compounds and compositions as ppar modulators
MEP1008A (xx)	2010-02-10	3-aminociklopentankarboksamidi kao modulatori receptora hemokina
PL1951692T3 (pl)	2011-02-28	Oksazolowe i tiazolowe modulatory PPAR
TNSN06382A1 (en)	2008-02-22	Compounds and compositions as ppar modulators
TW200603791A (en)	2006-02-01	Compounds and compositions as cathepsin S inhibitors
BRPI0606779A2 (pt)	2009-07-14	compostos e composições como moduladores de ppar